Key result
Valsartan monotherapy was associated with a lower incidence of new-onset diabetes compared to non-RAS inhibitors.
Why the study?
Does valsartan monotherapy reduce the incidence of new on-set diabetes in Chinese hypertensive patients compared to non-RAS agent monotherapy?
Cohort (n=29,295)
Does valsartan monotherapy reduce the incidence of new on-set diabetes in Chinese hypertensive patients compared to non-RAS agent monotherapy?
Valsartan monotherapy is associated with a lower risk of new-onset diabetes compared to non-RAS inhibitors, particularly calcium channel blockers, in hypertensive patients.
Answers are grounded in this paper and cite their sources.
May support valsartan preference to lower diabetes risk; hypothesis-generating and requires randomized confirmation.
This study aimed to compare the real-world effectiveness of valsartan and non renin-angiotensin system (non-RAS) agent monotherapy on the incidence of new on-set diabetes (NOD) in Chinese hypertensive patients. It was based on an electronic Health Recording System database from Minhang District of Shanghai. Hypertensive patients aged ≥18 years continuously taking either valsartan or non-RAS agent monotherapy for >12 months were included. Hazard ratios (HR) of NOD events were estimated using propensity score matching method and multivariate regression. Of 29295 patients, there were 2107 in valsartan group, 21397 in CCB group, 4094 in β-blockers group and 1697 in diuretics group. Two-year follow-up revealed NOD rates of 11.09 and 14.22 per 100 persons per year in valsartan and non-RAS inhibitor groups (HR = 0.77, 95% confidence interval 0.65-0.93, P = 0.006), respectively. Among non-RAS agents, CCB group had the highest incidence of NOD (21.72 per 100 persons per year). Comparisons between CCB sub-groups revealed the highest NOD incidence for nifedipine, followed by amlodipine and felodipine. NOD incidences in β-blockers and diuretics groups (11.70 and 10.50 per 100 persons per year, respectively) were not significantly different from valsartan group. Compared with non-RAS inhibitors, particularly CCBs, valsartan could significantly reduce the incidence of NOD.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2018) conducted a cohort in Hypertension (n=29,295). Valsartan vs. Non-RAS agent monotherapy was evaluated on Incidence of new on-set diabetes (NOD) (HR 0.77, 95% CI 0.65-0.93, p=0.006). Valsartan monotherapy was associated with a lower incidence of new-onset diabetes compared to non-RAS inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: